thiotepa has been researched along with (pPNET) Peripheral Primitive Neuroectodermal Tumors in 3 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT." | 5.10 | High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. ( Alloisio, M; Balzarotti, M; Bertuzzi, A; Castagna, L; Compasso, S; Nozza, A; Quagliuolo, V; Santoro, A; Siracusano, L; Soto Parra, H, 2002) |
| "ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2." | 2.68 | A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. ( Balis, FM; Bleyer, WA; Broxson, E; Geyer, JR; Heideman, R; Krailo, MD; Poplack, D; Sato, JK, 1996) |
| " The optimal dosage and schedule was 40 mg kg-1 daily for 5 days." | 1.29 | Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. ( Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vassal, G | 1 |
| Terrier-Lacombe, MJ | 1 |
| Bissery, MC | 1 |
| Vénuat, AM | 1 |
| Gyergyay, F | 1 |
| Bénard, J | 1 |
| Morizet, J | 1 |
| Boland, I | 1 |
| Ardouin, P | 1 |
| Bressac-de-Paillerets, B | 1 |
| Gouyette, A | 1 |
| Geyer, JR | 1 |
| Balis, FM | 1 |
| Krailo, MD | 1 |
| Heideman, R | 1 |
| Broxson, E | 1 |
| Sato, JK | 1 |
| Poplack, D | 1 |
| Bleyer, WA | 1 |
| Bertuzzi, A | 1 |
| Castagna, L | 1 |
| Nozza, A | 1 |
| Quagliuolo, V | 1 |
| Siracusano, L | 1 |
| Balzarotti, M | 1 |
| Compasso, S | 1 |
| Alloisio, M | 1 |
| Soto Parra, H | 1 |
| Santoro, A | 1 |
2 trials available for thiotepa and (pPNET) Peripheral Primitive Neuroectodermal Tumors
| Article | Year |
|---|---|
A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Humans; Neoplasms; Neuroectode | 1996 |
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophos | 2002 |
1 other study available for thiotepa and (pPNET) Peripheral Primitive Neuroectodermal Tumors
| Article | Year |
|---|---|
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplati | 1996 |